Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is a single-arm, open label protocol evaluating the use of Cleviprex to rapidly control hypertension in patients who present with intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH), and that require ICP monitoring via ventriculostomy (External Ventricular Drain or EVD).
Full description
Inclusion Criteria:
The study population will be comprised of men and non-pregnant women age 18 years or older presenting with ICH or SAH that require ICP monitoring via ventriculostomy, and that require IV antihypertensive therapy to a) reduce the risk re-bleeding in SAH and b) reduce the risk of hematoma expansion over time due to further bleeding.
This study population will require rapid and sustained tight control of blood pressure between 110 to 140 mmHg.
Subjects may be included in the study if they meet all of the following criteria:
Exclusion Criteria:
Subjects will be excluded from the study if any of the following exclusion criteria apply prior to enrollment:
Patients excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal